Gilead Sciences acquired CymaBay Therapeutics, Inc. for ~$4.3 billion, a transaction announced in February 2024.
Acquired the liver-disease specialist for $32.50 per share in cash (total equity value ~$4.3 billion) to add seladelpar, a PPAR-delta agonist for primary biliary cholangitis under FDA priority review, expanding Gilead's liver portfolio.
Acquired the liver-disease specialist for $32.50 per share in cash (total equity value ~$4.3 billion) to add seladelpar, a PPAR-delta agonist for primary biliary cholangitis under FDA priority review, expanding Gilead's liver portfolio.
We are looking forward to advancing seladelpar by leveraging Gilead's long-standing expertise in treating and curing liver diseases. -- Daniel O'Day, Chairman and CEO, Gilead Sciences
Advisory firms were not disclosed for this transaction.